Ibrutinib is an FDA-approved irreversible bruton’s tyrosine kinase (BTK) inhibitor used to treat CLL and MCL [19], and clinical trials of ibrutinib are undergoing for classic Hodgkin’s lymphoma (CHL) (NCT02940301) and DLBCL (NCT03399513). This evidence concerns the gene BTK and Hodgkins lymphoma.